<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00882388</url>
  </required_header>
  <id_info>
    <org_study_id>COREA-volunteer</org_study_id>
    <nct_id>NCT00882388</nct_id>
  </id_info>
  <brief_title>The Effect of Celecoxib on the Antiplatelet Effect of Aspirin and Clopidogrel in Normal Volunteers</brief_title>
  <official_title>Phase 4 Study of the Effect of Celecoxib on the Antiplatelet Effect of Aspirin and Clopidogrel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

        -  The prevalence of arthritis which needs celecoxib prescription is high in patients with
           coronary artery disease.

        -  The main concern is that celecoxib would increase thrombogenicity by inhibiting the
           synthesis of prostacyclin in endothelial cells.

        -  It is not known whether the administration of celecoxib would deteriorate antiplatelet
           effects of aspirin and clopidogrel which are used after stenting.

      Methods:

        -  Healthy volunteers (n=40)

        -  Randomization into five subgroups

        -  aspirin, celecoxib, aspirin+celecoxib, aspirin+clopidogrel,
           aspirin+clopidogrel+celecoxib

        -  Medication schedule : medication of each drug for 6 days, blood samples at day 0 and day
           7

        -  Celecoxib 200mg twice a day, and/or aspirin 100mg daily, and/or clopidogrel 75 mg daily

        -  Platelet function test : light transmittance aggregometry and arachidonic acid
           metabolite assay among subgroups.

      Study hypothesis : The addition of celecoxib does not deteriorate antiplatelet function of
      aspirin and clopidogrel.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Light transmittance aggregometry : % of inhibition (ADP, collagen)</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine arachidonic metabolite assay</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ASA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>aspirin only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cele</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ASA + Cele</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ASA + Clo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ASA + Clo + Cele</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>aspirin 100 mg qd for 7 days</description>
    <arm_group_label>ASA</arm_group_label>
    <other_name>aspirin : Keun-Hwa Phamaceutical</other_name>
    <other_name>clopidogrel : sanofi-aventis</other_name>
    <other_name>celecoxib : Pfizer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
    <description>celecoxib 200 mg bid * 7 days</description>
    <arm_group_label>Cele</arm_group_label>
    <other_name>aspirin : Keun-Hwa Phamaceutical</other_name>
    <other_name>clopidogrel : sanofi-aventis</other_name>
    <other_name>celecoxib : Pfizer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin + celecoxib</intervention_name>
    <description>aspirin 100 mg qd + celecoxib 200 mg bid for 7 days</description>
    <arm_group_label>ASA + Cele</arm_group_label>
    <other_name>aspirin : Keun-Hwa Phamaceutical</other_name>
    <other_name>clopidogrel : sanofi-aventis</other_name>
    <other_name>celecoxib : Pfizer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin + clopidogrel</intervention_name>
    <description>asprin 100 mg qd + clopidogrel 75 mg qd for 7 days</description>
    <arm_group_label>ASA + Clo</arm_group_label>
    <other_name>aspirin : Keun-Hwa Phamaceutical</other_name>
    <other_name>clopidogrel : sanofi-aventis</other_name>
    <other_name>celecoxib : Pfizer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin + clopidogrel + celecoxib</intervention_name>
    <description>aspirin 100 mg qd + clopidogrel 75 mg qd + celecoxib 200 mg bid</description>
    <arm_group_label>ASA + Clo + Cele</arm_group_label>
    <other_name>aspirin : Keun-Hwa Phamaceutical</other_name>
    <other_name>clopidogrel : sanofi-aventis</other_name>
    <other_name>celecoxib : Pfizer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers including both men and women 20~30 years

          -  no abnormality in physical examination, 12-lead ECG, and routine laboratory test

        Exclusion Criteria:

          -  Subjects with cardiovascular disease, hemostatic disorder, hypersensitivity to NSAIDs
             and clopidogrel

          -  Women with a positive pregnancy test

          -  smoker

          -  chronic drinkers

          -  overweight exceeding 20% of standard body weight
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo-Soo Kim, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2009</study_first_submitted>
  <study_first_submitted_qc>April 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2009</study_first_posted>
  <last_update_submitted>December 15, 2013</last_update_submitted>
  <last_update_submitted_qc>December 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2013</last_update_posted>
  <responsible_party>
    <name_title>Hyo-Soo Kim</name_title>
    <organization>Seoul National University Hospital</organization>
  </responsible_party>
  <keyword>celecoxib</keyword>
  <keyword>platelet</keyword>
  <keyword>thrombosis</keyword>
  <keyword>Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

